Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm

Author(s): Sophie E. Rowbotham, Smriti M. Krishna, Corey S. Moran, Jonathan Golledge*

Journal Name: Current Drug Targets

Volume 19 , Issue 11 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Objective: This mini-review provides the rationale and updated progress for ongoing randomized controlled trials assessing fenofibrate and telmisartan efficacy to limit abdominal aortic aneurysm (AAA) growth.

Methods/Results: There remains an urgent need to identify a drug therapy that will limit AAA growth. Data from preclinical and human studies indicate that fenofibrate and telmisartan have the potential to slow aortic destruction. Fenofibrate has been shown to reduce serum and tissue levels of the proinflammatory protein osteopontin, as well as reducing macrophage recruitment to the aortic wall, both of which are integral processes in the development and progression of AAAs. Telmisartan acts via blockade of the angiotensin II receptor, type 1, and also as a peroxisome proliferator-activated receptor gamma agonist. In turn, this inhibits the production of a range of biomarkers associated with AAA progression, including transforming growth factor-beta one, osteoprotegerin, osteopontin and matrix metalloproteinase- 9. Based on these findings, there are currently three randomized controlled trials assessing both fenofibrate and telmisartan as potential interventions to limit aneurysm growth in AAA patients.

Conclusion: Fenofibrate and telmisartan have potential as repurposed medications to limit AAA growth, and randomized trials for further assessment in AAA patients are ongoing.

Keywords: Abdominal aortic aneurysm, telmisartan, fenofibrate, osteopontin, angiotensin, clinical trial.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [1241 - 1246]
Pages: 6
DOI: 10.2174/1389450119666171227224655
Price: $65

Article Metrics

PDF: 30